Eisai currently works across Europe in the areas of Alzheimer’s disease, gastro-intestinal disorders, epilepsy, cervical dystonia and severe, chronic pain, and is moving into neurology, cancer and critical care with its development portfolio.
Eisai's medicines in Europe include Aricept® (donepezil hydrochloride) used in the treatment of Alzheimer's disease, Pariet® (rabeprazole sodium) a proton pump inhibitor (PPI) used in the treatment of gastro-intestinal disorders, Zonegran® (zonisamide) for the treatment of epilepsy, Inovelon® (rufinamide) for Lennox Gastaut Syndrome, NeuroBloc® (botulinum toxin type B) for cervical dystonia and Prialt® (ziconotide) for severe, chronic pain.
Eisai has recently acquired the European marketing rights for Zebinix® (eslicarbazepine acetate) for epilepsy and plans to launch it across the EU during 2009 and into 2010.
Eisai plans to bring a number of new products to market in the coming years including potential new treatments for Alzheimer’s disease, epilepsy and multiple sclerosis in the neurology area in addition to novel cancer and critical care treatments.
For full Summaries of Product Characteristics please refer to www.emc.medicines.org.uk.
Eisai has identified a number of key franchise areas (where we have compounds at each phase of development in the pipeline) which include neuroscience, oncology, vascular and immunology. By targeting treatments for specific indications in selected therapeutic areas and then ensuring we have a flow of new products, indications, and formulations in these areas, we can be more productive and efficient.
To help create breakthrough new treatments that fulfil unmet medical needs, Eisai has established Product Creation Units (PCUs) to match our key franchise areas. These units are accountable from discovery to regulatory filing of cutting edge innovative treatments. They are supported by a number of Core Functional Units (CFUs) which provide the required strength in technology and regulatory know-how to promote the development of new therapies.